Contribute Try STAT+ Today

Pharma

Taking stock of the drug industry, from the lab to the medicine chest. For a weekly update, sign up for our free Pharmalot newsletter. And subscribe to STAT+ for exclusive coverage and analysis of the pharma industry — from drug pipelines to boardroom shakeups.

Johnson & Johnson sign

Pharmalot By Ed Silverman

States reach $26 billion deal with three wholesalers and J&J to end opioid lawsuits

“This epidemic was created by an army of pharmaceutical executives,” said Pennsylvania Attorney General Josh Shapiro.

magnifying glass w/ reports

Pharmalot By Ed Silverman

Most clinical trials failed to meet U.S. transparency requirements for recently approved drugs

Latin America vaccine negotiations illo

Pharma By Madlen Davies, Ivan Ruiz, Jill Langlois, and Rosa Furneaux — The Bureau of Investigative Journalism

‘Held to ransom’: Pfizer plays hardball in Covid-19 vaccine negotiations with Latin American countries

Paper cup pills nonadherent noncompliant

Pharmalot By Ed Silverman

FDA plans to study whether pharma reps at conference exhibit booths are telling the truth

Porous Silica Nanoparticles

Biotech By Elizabeth Cooney

How nanotechnology helps mRNA Covid-19 vaccines work

All Coverage

Pharmalot By Elizabeth Cooney

Pharmalittle: Biogen’s ‘symptom quiz’ for Aduhelm draws fire; most U.S. clinical trials flunk transparency rules

Pharmalot By Ed Silverman

Pharmalittle: Biogen defends its controversial Alzheimer’s drug; critics pan Pfizer plan for Covid-19 shot production in Africa

advertisement

Pfizer Albert Bourla

Pharmalot By Ed Silverman

Pfizer looks to widen access to Covid-19 vaccine in Africa, but advocates say it doesn’t go far enough

Pharmalot By Ed Silverman

Pharmalittle: Pfizer cuts deal for Covid-19 shot to be partially made in South Africa; wholesalers to pay $1.1b to NY to settle opioid suit

OPIOID photo ILLUSTRATION

Pharmalot By Ed Silverman

Three pharma wholesalers reach a $1.1 billion deal with New York over the opioid crisis

Painkillers

Pharmalot By Ed Silverman

As a key hearing nears, Justice Department calls Purdue’s bankruptcy plan unconstitutional

Pharma By Ed Silverman

STAT+ Conversations: the revitalization of the antibiotic drug pipeline

Pharmalot By Ed Silverman

Pharmalittle: Wholesalers near deal over opioid litigation; pharma gives $67,400 to Peters for trying to torpedo drug pricing bill

Patent folder

Pharmalot By Ed Silverman

Advocates urge Biden to name patent office director that could transform drug pricing

money pile

Pharmalot By Ed Silverman

Dutch authorities fine drug maker $23 million for ‘excessive’ pricing of a rare disease drug

Pharmalot By Ed Silverman

Pharmalittle: Pfizer seeks full FDA approval for its Covid-19 vaccine; CT attorney general calls some Sacklers ‘entitled thugs’

FDA stop sign

The Pharmalot View By Ed Silverman

Too close for comfort: FDA shouldn’t loosen conflict rules for its expert panels

Painkillers

Pharmalot By Ed Silverman

Amid Purdue bankruptcy talks, Connecticut attorney general accuses some Sacklers of intimidation

Pharmalot By Elizabeth Cooney

Pharmalittle: ICER medical experts find no benefit for Aduhelm; FDA panel votes down Fibrogen’s anemia drug

Pharmalot Coming/Going STILL

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Biogen

Pharmalot By Ed Silverman

Expert panel votes unanimously that Biogen Alzheimer’s drug doesn’t offer patient benefits

Bribery

Pharmalot By Ed Silverman

U.K. issues record fine to drug makers for price gouging and collusion schemes

Pharmalot By Ed Silverman

Pharmalittle: FDA head admits possible missteps in Alzheimer’s drug approval; two major health systems won’t administer Biogen drug

Pharmalot By Ed Silverman

FDA scolds Amgen over a misleading ad that could deter use of biosimilar versions of its drug

Pharmalot By Ed Silverman

Pharmalittle: Half-dozen big insurers won’t cover new Alzheimer’s drug; Medicaid could spend up to $2.2 billion on the Biogen drug

Judge's gavel

Pharmalot By Ed Silverman

Insulin makers and pharmacy benefit managers must face racketeering claims in a lawsuit

David Ricks

STAT Summit By Elizabeth Cooney

‘Aduhelm left room’: Lilly CEO eyes competition with Biogen Alzheimer’s drug

Cambridge: Biogen

Pharmalot By Ed Silverman

Biogen’s new Alzheimer’s drug could cost Medicaid up to $2.2 billion a year

Pharmalot By Ed Silverman

Pharmalittle: Medicare starts coverage review for Biogen Alzheimer’s drug; U.S. needs more data before deciding on Covid booster shot